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Ullrich congenital muscular dystrophy (UCMD) corresponds to the severe 
end of the clinical spectrum of neuromuscular disorders caused by mutations 
in the genes encoding collagen VI (COL VI). We studied four unrelated 
families with six affected children that had typical UCMD with dominant 
and recessive inheritance.
Materials & Methods
Four unrelated Iranian families with six affected children with typical 
UCMD were analyzed for COLVI secretion in skin fibroblast culture and 
the secretion of COLVI in skin fibroblast culture using quantitative RT–PCR 
(Q-RT-PCR), and mutation identification was performed by sequencing of 
complementary DNA.
Results
COL VI secretion was altered in all studied fibroblast cultures. Two affected 
sibs carried a homozygous nonsense mutation in exon 12 of COL6A2, 
while another patient had a large heterozygous deletion in exon 5-8 of 
COL6A2. The two other affected sibs had homozygote mutation in exon 24 
of COL6A2, and the last one was homozygote in COL6A1.
Conclusion
In this study, we found out variability in clinical findings and genetic 
inheritance among UCMD patients, so that the patient with complete 
absence of COLVI was severely affected and had a large heterozygous 
deletion in COL6A2. In contrast, the patients with homozygous deletion had 
mild to moderate decrease in the secretion of COL VI and were mildly to 
moderately affected. 
Keywords: Ullrich congenital muscular dystrophy; Collagen type VI, 
COL6A1, COL6A2
Introduction
Congenital muscular dystrophy (CMD) constitutes a heterogeneous group of 
disorders characterized by muscle weakness and hypotonia at birth (1). These 
disorders vary in severity, symptoms, outcomes, pathological findings, and genes 
(1).
In 1930, Ullrich described two unrelated patients with CMD, and the disorder was 
described as scleroatonic muscular dystrophy with peculiar clinical findings (2,3). 
The clinical manifestations of UCMD are muscle weakness of early onset, proximal 
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these genes, which were 
not transmitted but acquired as dominant de novo (9). 
UMCD, [MIM] # 254090 and Bethlem myopathy (BM), 
[MIM] # 158810, are two extremes of a contiguous 
clinical spectrum, which intermediate observed 
phenotype (14). Classical UCMD is the severe end and 
classical BM corresponds to a milder form with late 
onset and static course (5). 
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joint contractures, distal hyperextensibility, and normal 
intelligence (2,3). 
Decreased fetal movement is often noted in the prenatal 
period. Muscle weakness is usually severe and, patients 
typically never walk independently, or do so only for 
a short time (1,4,5) Over time, there is development 
of spinal rigidity and kyphoscoliosis and variable 
contractures in proximal joint, distal joint hyperlaxity, 
and tight Achilles tendons (1,4,5).
In the first or second decade of life, respiratory failure 
has been reported as a common cause of death unless 
treated by nocturnal respiratory support. Failure to thrive 
is common. Cardiac involvement is generally absent 
(1,4-6). Other distinctive features observed in UCMD 
patients are as follows: congenital hip dislocation, 
torticollis, multiple joint contractures of knees and 
elbows, kyphotic contracture of the spine, and skin 
changes, such as hypertrophic scars and hyperkeratosis 
follicularis (1,4-6). Serum creatine kinase (CK) levels 
are usually normal or mildly increased (4). 
Electromyography (EMG) shows action potentials 
of low amplitude and short duration (7). Variable 
pathology ranging from non-specific mild myopathic 
changes to more dystrophic-like changes, can be 
observed in muscle biopsies of UCMD patients. The 
spectrum includes variation in fibre size, type 1 fibre 
predominance, increase in endomysial connective 
tissue, increase in numbers of internal nuclei, and focal 
areas of necrosis, along with more indirect evidence of 
muscle fibre regeneration, including the presence of 
fibres containing fetal myosin (1,4,8,10).
This disorder was originally identified as a recessive 
condition with homozygous and compound 
heterozygous mutations in one of the three genes 
(COL6A1, COL6A2, and COL6A3) encoding three 
chains, which are assembled and secreted to form 
collagen VI (ColVI) microfibrils. Nevertheless, over 
the last few years, a number of patients presenting with 
clinical manifestations of severe UCMD were shown to 
carry heterozygous mutations in 
Materials & Methods
We studied six affected children (5 males, 1 female) 
from four unrelated Iranian families. All of them were 
diagnosed with a classical UCMD Phenotype. The 
parents were consanguineous, healthy, and normal 
according to the clinical examination. According to 
ethical rules, all parents signed an informed written 
consent for photography, genetic analysis, blood 
sampling, and skin biopsy.
The affected child from family A was a 6-year-old boy. 
His mother reported decreased fetal movement during 
pregnancy. He was born at 39 weeks of gestation by 
cesarean section, due to breech position. His birth 
weight, length, and head circumference were all within 
normal limits (2800 gram, 48, and 34 cm, respectively). 
At birth, the patient presented with severe hypotonia, 
contractures in knees, and flexion deformity of elbows 
and rigidity of spine. At the age of 10 months, he 
showed limited movements of shoulder and hip and 
hyperextensibility of fingers, wrists, toes, and ankles. 
Torticollis, stiff neck, and severe kyphoscoliosis were 
also noted as the disease progressed. He could sit only 
with support at the age of 2 only for six months and 
never achieved the ability to stand and walk. His first 
visit at our centre was at the age of 6 years. He showed 
severe clinical manifestations of UCMD with normal 
intelligence. All biochemical, endocrinological, and 
metabolic tests were normal except for a slight increase 
of CK levels [255 IU/L (Normal range: 50-200 IU/L)]. 
EMG showed a chronic myopathic process. The child 
progressively developed respiratory failure, underwent 
tracheostomy, and was eventually put on nocturnal 
positive pressure mechanical ventilation at the age of 
8. However, he passed away six months later due to 
pneumonia (Figure 1).
Family B had two affected and one healthy offsprings. 
The first child was a healthy aged 12-year-old girl. 
The second child was a 10-year-old affected girl, and 
the third was a 7-year-old affected boy. Both affected 
children were born at 40 weeks of gestation following 
normal vaginal delivery. Their birth weight, head 
circumference and height were within normal limits. 
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Hypotonia and knee stiffness were noted at birth. They 
were examined in our centre when the girl was 10 and 
the boy was 7 years old. They could sit with support 
and their cognition was normal. Both of them had 
torticollis, stiff neck, limited movement of elbows and 
knees, kyphoscoliosis, and hyperextensibility of wrists, 
fingers, ankles, and toes. They never achieved ability to 
stand and walk independently.
All biochemical, endocrinological, and metabolic 
tests were normal. EMG showed a chronic myopathic 
process in both. They are still alive after three years 
with a slow progression in skeletal deformity. 
Family C had two affected sons. The first son 
was 7 years old and the second son was 2 year old. 
Both of them were born at 40 weeks of gestation 
following normal delivery. Their birth weight, head 
circumference, and height were within normal limits. 
They were hypotonic at birth without any contractures. 
They were examined in our center when the first son 
was 7 and second was 2 year old. The older son could 
walk with support for 2 years from 4 to 6 years of age, 
but he lost the ability of walking after 6. The younger 
son has not been able to walk yet. Their cognition was 
normal. The older son had contracture of elbows and 
knees as well as torticollis, scoliosis, and hyperlaxity 
of fingers, toes, wrist, and ankle,. The younger son had 
hyperextensibility of wrist, fingers, toes and knees, 
without any contractures in joints. All biochemical, 
endocrinological and metabolic tests were normal. 
EMG of the older son showed a chronic myopathic 
process. They are still alive after one year. 
Family D had a 11-year-old affected son. His mother 
reported decreased fetal movements. Birth weight, 
length, and head circumference were all within normal 
limits (2900 gram, 50 cm, and 34 cm, respectively). 
At birth, the patient presented with severe hypotonia 
without any contractures. He was examined in our 
center at the age of 11. He could sit with support at 
the age of 12 months, but he never achieved ability to 
walk. His cognition was normal. He had contracture 
of shoulders, hips, knees, and ankles, which were first 
noted at 4-5 years. He had hyperextensibility in fingers 
but not in toes. He also had an ulnar deviation in his 
wrist, and hyperkeratosis follicularis. All biochemical, 
endocrinological, and metabolic tests were normal 
EMG showed chronic myopathic process. 
Collagen VI immunolabeling on cultured skin 
fibroblasts 
Muscle cryosections were not available, so, we did skin 
biopsy for six patients. ColVI immunolabeling were 
carried out on the skin fibroblasts of one control and six 
patients.
Col VI secretion was investigated on confluent fibroblasts 
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Fig 1. Family A: a, torticollis; b, scoliosis; c, hyperextensibility of wrist; d, 
hyperextensibiliy of fingers.
17
Iran J Child Neurol. Vol 7 No 3 2013 Summer
cultured in the presence of 0.25 mM ascorbic acid for 
5 days, then, stained with the MAB 1944 antibody 
(Chemicon International), diluted 1:100, and incubated 
overnight at +4°C.
Slides were observed using an Axioplan 2 microscope 
(Zeiss) equipped with a HBO 100 mercury lamp 
(Zeiss) and representative images were obtained by the 
Metaview software.
RNA Extraction and Quantitative RT-PCR
Total RNA was extracted from confluent fibroblast cultures 
using Trizol® (Invitrogen) according to the manufacturer’s 
recommendations. cDNA prepared from 1 µg of total RNA 
using oligo (dT) 18 and superscript II reverse transcriptase 
as recommended by the manufacture. Chain specific 
transcripts were quantified from fibroblast-derived cDNA 
using quantitative RT-PCR on a LightCycler via primers 
hybridizing to the last C-terminal of each domain.
Genetic analysis 
Genomic DNA from patients and their parents was 
obtained from blood leukocytes by standard methods. 
Ullrich Congenital Muscular Dystrophy (UCMD): Clinical and Genetic Correlations
Fig 2. Pedigrees of UCMD families
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The coding regions of the genes were amplified from 
fibroblast-derived cDNA in several overlapping 
fragment (primers available on request), and sequenced 
on the ABI3730 capillary electrophoresis system. 
Sequences were compared with reference sequences, 
NM-001848.2 (COL6A1), NM-001849.3 (COL6A2), 
and NM-004369.3 (COL6A3). Each potentially 
pathogenic change was confirmed on genomic DNA 
from patient and their parents. All tests were done in 
GIS Institute in Paris.
Table 1. Primers Used in Quantitative RT-PCR





In four studied families, transcript levels of each gene 
were quantified using specific primers and revealed a 
distinct reduction of the COL6A2 mRNA species in the 
three families, while level of the COL6A1 was reduced 
in family D. COL6A3 mRNA were within the normal 
range in all families. These data clearly suggest that 
COL6A2 and COL6A1 gene carry the pathological 
mutations in these families.
Sequencing of mRNA from the affected boy of family 
A revealed a large heterozygous deletion encompassing 
exons 5 to 8 of the COL6A2 transcript. No additional 
mutations were detected in COL6A1, COL6A2 and 
COL6A3 genes. The deletion was not present in the 
parents, thus, the COL6A2 deletion occurred de novo. 
Concerning family B, sequencing of the coding 
regions of the COL6A2 gene revealed a homozygous 
nonsense mutation in exon 12 (c.1096 C>T) leading 
to a premature termination codon (p.R366X), in both 
siblings and at the heterozygous state in both parents. 
The occurance of the premature stop codon most 
likely triggered the nonsense mediated mRNA decay 
(NMD) pathway leading to the degradation of the 
corresponding transcripts and the low levels observed 
by quantitative RT-PCR. 
In family C, analysis of cDNA sequence showed a 
homozygous deletion of exon 24 [c.1771-1819 del] 
causing a shift in the reading frame at codon Glu591 
and creation of a premature stop codon at position 
[p.Glu591ThrfsX149].
In family D, a pathogenic mutation was identified that 
consisted of 259 base pairs of exon 19 in the cDNA 
and resulted in a frame shift in the reading frame, and 
in homozygote mutation of COL6A1. All Mutations 
was confirmed on genomic DNA from the patients 
and their parents. COLVI expression and secretion 
pattern in skin fibroblast cultures was normal in control 
fibroblasts and abnormal secretion was detected in all 
the patients’ fibroblast cultures. 
COLVI secretion was completely absent in first patient, 
strongly reduced in family B and slightly reduced in 
family C and D (Figure 3 and supporting information 
in Table 2).
Discussion
UCMD is a disorder characterized by muscle weakness, 
proximal joint contractures, and hyperlaxity of 
distal joints. It has long been considered to follow an 
autosomal recessive mode of inheritance. The pattern of 
inheritance was challenged when patients with severe 
clinical findings compatible with UCMD were shown 
to have heterozygous deletions in COL6A1, COL6A2, 
or COL6A3. The first case of autosomal dominant 
inheritance was reported by Pan et al. (2003). The patient 
had a de novo heterozygous deletion of COL6A2 gene 
that resulted in a severe phenotype of UCMD, however, 
that particular deletion was not present in their parents (9).
Baker et al. (2005) reported three patients with 
heterozygous deletions in the COL6A1, COL6A2, 
COL6A3 genes. The study showed that these mutations 
Ullrich Congenital Muscular Dystrophy (UCMD): Clinical and Genetic Correlations
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act in a dominant mode and result in severe collagen VI 
deficiency (10).
Pace et al. (2008) reported 8 patients with heterozygous 
collagen VI mutations. All eight patients had 
heterozygous glycine mutations in the triple helix. These 
anomalies have already been associated with Bethlem 
and UCMD phenotypes (11). 
BM was first described in 1976 by Bethlem and 
Wijngaarden and was considered as an autosomal 
dominant condition. BM is generally a mild and late 
proximal myopathy with finger flexion contractures 
(12). Gualandi et al. (2009) and Foley et al (2009) both 
reported patients with BM with a recessive mode of 
inheritance (13,14).  
It is known that BM and UCMD represent opposite ends 
of a COLVI related disorders spectrum, in which patients 
with intermediate phenotypes could be considered to 
have either severe UCMD or mild BM (13).
BM is a mild disorder with major impact on adult life. 
Patients may have neonatal hypotonia or delayed motor 
milestones that can become symptomatic within the first 
or second decade of life. However, some adult patients 
remain unaware of weakness until late age (12).
BM is transmitted both as autosomal dominant and 
recessive disorder. It is associated with mutations in 
COL6A1, COL6A2, and COL6A3 (13).
UCMD has been considered a recessive condition with 
homozygous or compound heterozygous mutations in 
COL6A1, COL6A2, and COL6A3. However, studies 
have shown that heterozygous de novo deletions in 
COL6A1, COL6A2, and COL6A3 cause both severe 
UCMD and mild BM (13-15). 
Pace et al. indicated that COL6 mutations impair the COLVI 
synthesis pathway in different ways, and disease severity 
correlates with the assembly abnormality. In mildly 
affected patients, normal amounts of collagen VI were 
deposited in the fibroblasts, while in patients with severe 
disability, collagen VI was reduced in fibroblasts (11). 
Here we present 6 patients with early onset COLVI 
myopathy with a variable severity of presentation and 
progression, and harbouring mutations in one of the 
CoLVI encoding genes. Our first patient with large 
heterozygous deletion in exon 5 to 8 on COLA2 and 
absent secretion of COLVI in fibroblasts had severe 
Ullrich Congenital Muscular Dystrophy (UCMD): Clinical and Genetic Correlations
Fig 3. Collagen VI (COL VI) immunolabeling of control and patients derived cultured 
fibroblasts (A) Control fibroblasts formed a dense COLVI net. (B, C, D) COLVI 
immunolabeling in fibroblasts from patients as examples of complete secretion 
deficiency, strongly reduced secretion, reduced secretion, respectively
20
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contractures, respiratory failure with rapid progression 
to death. The siblings in the second family with 
homozygous deletion in exon 12 of COLA2 and strongly 
reduced COLVI secretion in fibroblasts had moderate 
phenotype of UCMD.
In Contrast, the siblings of the third family with 
homozygous deletion of exon 24 of COL6A2 and mild 
reduced COLVI secretion in fibroblasts, had milder 
phenotype of UCMD with slow progression. The last 
patient in the fourth family was homozygote in COL6A1 
and showed very slow progression of disease.
In conclusion, taking together all the results presented 
above, we found a correlation between the clinical 
severity and COLVI secretion in cultured fibroblasts, 
and genotype. 
The patient with complete absence of COLVI secretion 
was severely affected, and had a large heterozygous 
deletion in COL6 A2.
In contrast, the patients with homozygous deletions 
were mildly to moderately affected. More investigations 
should be performed in the future to show the mechanism 
of differences between autosomal recessive UCMD, 
autosomal dominant UCMD with severe phenotype, and 
autosomal dominant BM with mild phenotype.
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